|Articles|April 23, 2012

Thomson Reuters to Sell Healthcare Business to Veritas Capital

Read the full story: http://hcp.lv/IssSay

Source: ModernHealthcare.com

Thomson Reuters plans to sell its healthcare business to Veritas Capital for $1.25 billion in cash.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP

ByBrooke McCormick,Katherine Tobon, PharmD, BCOP

February 7th 2026

Patients spoke of navigating unwritten social rules around who could know about their hair loss and when concealment was expected. | Image credit: Creative Cat Studio - stock.adobe.com

Exploring Identity, Appearance Experiences Among Patients With Alopecia

ByAJMC Contributor

February 6th 2026

pill with water -New Africa - stock.adobe.com

5 Things to Know About the Oral GLP-1 Era

ByGiuliana Grossi

February 6th 2026

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

ByMary Caffrey

February 6th 2026

The mechanistic role of HP in CSU remains unclear, and whether HP is merely a marker of inflammation or an active contributor to disease processes warrants further investigation. | Image Credit: stock.adobe.com

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified

ByAJMC Contributor

February 6th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Thomson Reuters to Sell Healthcare Business to Veritas Capital

Newsletter

Related Content

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP

Exploring Identity, Appearance Experiences Among Patients With Alopecia

5 Things to Know About the Oral GLP-1 Era

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”

TrumpRx Launch Brings Savings—and Uncertainty

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP

5 Things to Know About the Oral GLP-1 Era